Liver abnormalities in cardiac diseases and heart failure

International Journal of Angiology

Volumn 20, Issue 3, 2011, Pages 135-142

  Alvarez, Alicia M ^a   Mukherjee, Debabrata ^a  

^a USA   (United States)

Author keywords

cardiac output; cardiovascular disease; Heart failure; hepatic congestion; liver dysfunction; pulsatile liver; shock liver

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ASPARTATE AMINOTRANSFERASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILIRUBIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GAMMA GLUTAMYLTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LACTATE DEHYDROGENASE; WARFARIN;

ABNORMAL LABORATORY RESULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOGENIC ISCHEMIC HEPATITIS; CENTRAL VENOUS PRESSURE; CLINICAL FEATURE; DRUG CLEARANCE; DRUG METABOLISM; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEART DISEASE; HEART FAILURE; HEART OUTPUT; HEART PERFUSION; HEART VENTRICLE FILLING; HEART VENTRICLE PRESSURE; HEPATITIS; HISTOPATHOLOGY; HUMAN; HYPOTENSION; INTERNATIONAL NORMALIZED RATIO; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER DYSFUNCTION; LIVER FUNCTION TEST; OXYGEN CONSUMPTION; PATHOGENESIS; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW;

EID: 80053018636     PISSN: 10611711     EISSN: 16155939     Source Type: Journal    
DOI: 10.1055/s-0031-1284434     Document Type: Review

References (45)

1. Hunt SA; American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005;46(6):e1-e82 (Pubitemid 41316530)
2. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119(14):1977-2016
3. Sherlock S. The liver in heart failure; relation of anatomical, functional, and circulatory changes. Br Heart J 1951;13(3): 273-293
4. Safran AP, Schaffner F. Chronic passive congestion of the liver in man. Electron microscopic study of cell atrophy and intralobular fibrosis. Am J Pathol 1967;50(3):447-463
5. Dunn GD, Hayes P, Breen KJ, Schenker S. The liver in congestive heart failure: a review. Am J Med Sci 1973; 265(3):174-189
6. Safran AP, Schaffner F. Chronic passive congestion of the liver in man. Electron microscopic study of cell atrophy and intralobular fibrosis. Am J Pathol 1967;50(3):447-463
7. Lefkowitch JH, Mendez L. Morphologic features of hepatic injury in cardiac disease and shock. J Hepatol 1986;2(3):313-327 (Pubitemid 16086595)
8. Weisberg IS, Jacobson IM. Cardiovascular diseases and the liver. Clin Liver Dis 2011;15(1):1-20
9. Henrion J, Minette P, Colin L, Schapira M, Delannoy A, Heller FR. Hypoxic hepatitis caused by acute exacerbation of chronic respiratory failure: a case-controlled, hemodynamic study of 17 consecutive cases. Hepatology 1999;29(2):427-433 (Pubitemid 29088446)
10. Mathurin P, Durand F, Ganne N, et al. Ischemic hepatitis due to obstructive sleep apnea. Gastroenterology 1995;109(5): 1682-1684
11. Henrion J, Schapira M, Luwaert R, Colin L, Delannoy A, Heller FR. Hypoxic hepatitis: clinical and hemodynamic study in 142 consecutive cases. Medicine (Baltimore) 2003;82(6): 392-406 (Pubitemid 37448566)
12. Ellenberg M, Osserman KE. The role of shock in the production of central liver cell necrosis. Am J Med 1951; 11(2):170-178
13. Killip T III, Payne MA. High serum transaminase activity in heart disease. Circulatory failure and hepatic necrosis. Circulation 1960;21:646-660
14. Clarke WT. Centrilobular hepatic necrosis following cardiac infarction. Am J Pathol 1950;26(2):249-255
15. Giallourakis CC, Rosenberg PM, Friedman LS. The liver in heart failure. Clin Liver Dis 2002;6(4):947-967; viii-ix (Pubitemid 36026457)
16. Seeto RK, Fenn B, Rockey DC. Ischemic hepatitis: clinical presentation and pathogenesis. Am J Med 2000;109(2):109-113
17. Birgens HS, Henriksen J, Matzen P, Poulsen H. The shock liver. Clinical and biochemical findings in patients with centrilobular liver necrosis following cardiogenic shock. Acta Med Scand 1978;204(5):417-421
18. Myers RP, Cerini R, Sayegh R, et al. Cardiac hepatopathy: clinical, hemodynamic, and histologic characteristics and correlations. Hepatology 2003;37(2):393-400 (Pubitemid 36152539)
19. Gitlin N, Serio KM. Ischemic hepatitis: widening horizons. Am J Gastroenterol 1992;87(7):831-836
20. Cassidy WM, Reynolds TB. Serum lactic dehydrogenase in the differential diagnosis of acute hepatocellular injury. J Clin Gastroenterol 1994;19(2):118-121 (Pubitemid 24267564)
21. Allen LA, Felker GM, Pocock S, et al; CHARM Investigators. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail 2009;11(2):170-177
22. Shinagawa H, Inomata T, Koitabashi T, et al. Prognostic significance of increased serum bilirubin levels coincident with cardiac decompensation in chronic heart failure. Circ J 2008;72(3):364-369 (Pubitemid 351600627)
23. Denis C, De Kerguennec C, Bernuau J, Beauvais F, Cohen SolalA. Acute hypoxic hepatitis ('liver shock'): still a frequently overlooked cardiological diagnosis. Eur J Heart Fail 2004;6(5): 561-565 (Pubitemid 39070509)
24. van Deursen VM, Damman K, Hillege HL, van Beek AP, van Veldhuisen DJ, Voors AA. Abnormal liver function in relation to hemodynamic profile in heart failure patients. J Card Fail 2010;16(1):84-90
25. Lau GT, Tan HC, Kritharides L. Type of liver dysfunction in heart failure and its relation to the severity of tricuspid regurgitation. Am J Cardiol 2002;90(12):1405-1409 (Pubitemid 35449493)
26. Camposilvan S, Milanesi O, Stellin G, Pettenazzo A, Zancan L, D'Antiga L. Liver and cardiac function in the long term after Fontan operation. Ann Thorac Surg 2008;86(1):177-182
27. Lowe MD, Harcombe AA, Grace AA, Petch MC. Lesson of the week: restrictive-constrictive heart failure masquerading as liver disease. BMJ 1999;318(7183):585-586 (Pubitemid 29188964)
28. Kirsch M, Fleshler B. Deceptive liver histology delays diagnosis of cardiac ascites. South Med J 1992;85(11):1151-1152
29. Solano FX Jr, Young E, Talamo TS, Dekker A. Constrictive pericarditis mimicking Budd-Chiari syndrome. Am J Med 1986;80(1):113-115 (Pubitemid 16134813)
30. Arora A, Tandon N, Sharma MP, Acharya SK. Constrictive pericarditis masquerading as Budd-Chiari syndrome. J Clin Gastroenterol 1991;13(2):178-181
31. Sokol SI, Cheng A, Frishman WH, Kaza CS. Cardiovascular drug therapy in patients with hepatic diseases and patients with congestive heart failure. J Clin Pharmacol 2000;40(1): 11-30
32. Daskalopoulos G, Pinzani M, Murray N, Hirschberg R, Zipser RD. Effects of captopril on renal function in patients with cirrhosis and ascites. J Hepatol 1987;4(3):330-336 (Pubitemid 17080471)
33. New Horizons in Antihypertensive Therapy. Gopten (trandolapril). Ludwigshafen: Knoll AG. 1992
34. Brookman LJ, Rolan PE, Benjamin IS, et al. Pharmacokinetics of valsartan in patients with liver disease. Clin Pharmacol Ther 1997;62(3):272-278 (Pubitemid 27417792)
35. Gillis JC, Markham A. Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs 1997;54(6):885-902 (Pubitemid 27526898)
36. Markham A, Goa KL. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997;54(2):299-311 (Pubitemid 27361837)
37. Marino MR, Langenbacher KM, Raymond RH, Ford NF, Lasseter KC. Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis. J Clin Pharmacol 1998;38(4):347-356 (Pubitemid 28194175)
38. Kirch W, Schäfer-Korting M, Mutschler E, Ohnhaus EE, Braun W. Clinical experience with atenolol in patients with chronic liver disease. J Clin Pharmacol 1983;23(4): 171-177 (Pubitemid 13131442)
39. Buchi KN, Rollins DE, Tolman KG, Achari R, Drissel D, Hulse JD. Pharmacokinetics of esmolol in hepatic disease. J Clin Pharmacol 1987;27(11):880-884
40. Zaman R, Jack DB, Wilkins MR, Kendall MJ. Lack of effect of liver disease on the pharmacokinetics of acebutolol and diacetolol: a single dose study. Biopharm Drug Dispos 1985; 6(2):131-137 (Pubitemid 15092214)
41. Fredrick MJ, Pound DC, Hall SD, Brater DC. Furosemide absorption in patients with cirrhosis. Clin Pharmacol Ther 1991;49(3):241-247
42. Nul DR, Doval HC, Grancelli HO, et al. Heart rate is a marker of amiodarone mortality reduction in severe heart failure. The GESICA-GEMA Investigators. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina-Grupo de Estudios Multicéntricos en Argentina. J Am Coll Cardiol 1997;29(6):1199-1205
43. Garguichevich JJ, Ramos JL, Gambarte A, et al. Effect of amiodarone therapy on mortality in patients with left ventricular dysfunction and asymptomatic complex ventricular arrhythmias: Argentine Pilot Study of Sudden Death and Amiodarone (EPAMSA). Am Heart J 1995a;130(3 Pt 1): 494-500
44. Go AS, Lee WY, Yang J, Lo JC, Gurwitz JH. Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA 2006;296(17):2105-2111 (Pubitemid 44664705)
45. Shinagawa H, Inomata T, Koitabashi T, et al. Increased serum bilirubin levels coincident with heart failure decompensation indicate the need for intravenous inotropic agents. Int Heart J 2007;48(2):195-204 (Pubitemid 46603427)